Last reviewed 2026-04-23 · How we verify

bifeprunox, olanzapine

Bifeprunox is a selective dopamine D2 receptor antagonist and serotonin 5-HT2A receptor antagonist, and olanzapine is a serotonin 5-HT2A receptor antagonist and a dopamine D2 receptor antagonist.

Bifeprunox is a selective dopamine D2 receptor antagonist and serotonin 5-HT2A receptor antagonist, and olanzapine is a serotonin 5-HT2A receptor antagonist and a dopamine D2 receptor antagonist. Used for Schizophrenia, Bipolar disorder.

At a glance

Mechanism of action

Bifeprunox and olanzapine work by blocking the action of dopamine and serotonin in the brain, which helps to reduce symptoms of schizophrenia and bipolar disorder. Bifeprunox has a more selective mechanism of action compared to olanzapine, with a higher affinity for the dopamine D2 receptor. This may contribute to its potential therapeutic benefits and reduced side effects.

Approved indications

• Schizophrenia
• Bipolar disorder

Common side effects

• Weight gain
• Dyslipidemia
• Hyperprolactinemia
• Somnolence
• Dry mouth

Key clinical trials

• Bifeprunox in the Treatment of Schizophrenia (PHASE3)
• Patient-reported Outcomes in the Treatment of Schizophrenia (PHASE3)
• Switch Study of Existing Atypical Antipsychotics to Bifeprunox (PHASE3)
• Study Comparing the Affect of Bifeprunox Vs Olanzapine on Weight During the Treatment of Outpatients With Schizophrenia. (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• bifeprunox, olanzapine CI brief — competitive landscape report
• bifeprunox, olanzapine updates RSS · CI watch RSS
• Wyeth is now a wholly owned subsidiary of Pfizer portfolio CI